1034305-17-3 Usage
Description
Benzo[b]thiophene, 2-[(5-bromo-2-fluorophenyl)methyl]is a chemical compound characterized by a molecular structure that features a benzene ring fused to a thiophene ring, along with a 2-[(5-bromo-2-fluorophenyl)methyl] substituent. Benzo[b]thiophene, 2-[(5-broMo-2-fluorophenyl)Methyl]is recognized for its significance in the synthesis of pharmaceuticals, agrochemicals, and materials, and is valued for its potential applications in medicinal chemistry research and drug development.
Uses
Used in Pharmaceutical Industry:
Benzo[b]thiophene, 2-[(5-bromo-2-fluorophenyl)methyl]is utilized as a building block in the synthesis of new drugs due to its unique molecular structure and potential biological activities. It is particularly valuable for its role in the development of pharmaceuticals with anti-cancer, anti-inflammatory, and antibacterial properties.
Used in Agrochemical Industry:
In the agrochemical sector, Benzo[b]thiophene, 2-[(5-bromo-2-fluorophenyl)methyl]serves as a key component in the creation of new agrochemicals, leveraging its chemical properties to enhance the effectiveness of products designed for agricultural applications.
Used in Materials Science:
Benzo[b]thiophene, 2-[(5-bromo-2-fluorophenyl)methyl]is also employed in materials science for the development of novel materials, capitalizing on its structural attributes to improve material properties or introduce new functionalities.
Used in Medicinal Chemistry Research:
Benzo[b]thiophene, 2-[(5-broMo-2-fluorophenyl)Methyl]is applied in medicinal chemistry research as a promising candidate for exploring its biological activities and potential therapeutic effects, with a focus on its anti-cancer, anti-inflammatory, and antibacterial properties, which could lead to the discovery of new treatments and therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 1034305-17-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,4,3,0 and 5 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1034305-17:
(9*1)+(8*0)+(7*3)+(6*4)+(5*3)+(4*0)+(3*5)+(2*1)+(1*7)=93
93 % 10 = 3
So 1034305-17-3 is a valid CAS Registry Number.
1034305-17-3Relevant articles and documents
Method for synthesizing ipragliflozin
-
, (2018/07/30)
The invention discloses a method for synthesizing ipragliflozin. The method comprises the following steps: (1) generating alkylation reaction by formula-4 compound and formula-5 compound to generate aformula-6 compound; (2) carrying out deprotection on the formula-6 compound to generate a formula-7 compound, i.e., ipragliflozin. Compared with the prior art, the preparation method disclosed by theinvention is characterized in that adopted starting raw materials are cheap and can be easily obtained, a synthesis route is short, operation is convenient, cost is lower and general yield is high. The method conforms to the concept of green chemistry and is suitable for industrial production. (The formulas are shown in the description.).
Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus
Imamura, Masakazu,Nakanishi, Keita,Suzuki, Takayuki,Ikegai, Kazuhiro,Shiraki, Ryota,Ogiyama, Takashi,Murakami, Takeshi,Kurosaki, Eiji,Noda, Atsushi,Kobayashi, Yoshinori,Yokota, Masayuki,Koide, Tomokazu,Kosakai, Kazuhiro,Ohkura, Yasufumi,Takeuchi, Makoto,Tomiyama, Hiroshi,Ohta, Mitsuaki
, p. 3263 - 3279 (2012/07/14)
A series of C-glucosides with various heteroaromatics has been synthesized and its inhibitory activity toward SGLTs was evaluated. Upon screening several compounds, the benzothiophene derivative (14a) was found to have potent inhibitory activity against SGLT2 and good selectivity versus SGLT1. Through further optimization of 14a, a novel benzothiophene derivative (14h; ipragliflozin, ASP1941) was discovered as a highly potent and selective SGLT2 inhibitor that reduced blood glucose levels in a dose-dependent manner in diabetic models KK-Ay mice and STZ rats.